Daicel Corporation
Stock Price Chart
2026/06/11 UpdatedPrice Trend
2026/06/11 UpdatedPrice & Trading Details
2026/06/11 UpdatedPRICE
TRADING
Analyst Recommendations 8 analysts
Updated 2026/06/05Earnings Calendar
Updated 2026/06/05Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/02/04 | ¥40.17 | ¥64.09 | +59.6% |
| 2025/11/05 | ¥57.20 | ¥34.61 | -39.5% |
| 2025/07/31 | ¥49.90 | ¥36.29 | -27.3% |
| 2025/05/13 | ¥42.57 | ¥21.14 | -50.3% |
Shareholder Composition
Updated 2026/06/05Major Holders
Updated 2026/06/05| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
4.4M | +2.83% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
3.6M | +2.46% | |
|
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Intl Discovery Fd.
|
2.9M | -3.68% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.2M | +2.94% | |
|
Pear Tree Funds-Pear Tree Polaris Foreign Value Small Cap Fund
|
1.7M | 0.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.7M | +0.52% |
Dividend History
Updated 2026/06/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥30 | -50.0% |
| 2025 | ¥60 | +9.1% |
| 2024 | ¥55 | +22.2% |
| 2023 | ¥45 | +25.0% |
| 2022 | ¥36 | - |
Financial Performance
2026/06/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥467,937M | ¥538,026M | ¥558,056M | ¥586,531M |
| Gross Profit | ¥138,607M | ¥145,811M | ¥159,280M | ¥164,746M |
| Operating Income | ¥50,697M | ¥47,508M | ¥62,393M | ¥61,011M |
| Pretax Income | ¥47,644M | ¥56,399M | ¥77,698M | ¥67,480M |
| Net Income | ¥31,254M | ¥40,682M | ¥55,834M | ¥49,480M |
| EPS | ¥104.14 | ¥138.87 | ¥138.87 | ¥181.44 |
| Operating Margin | 10.83% | 8.83% | 11.18% | 10.40% |
| Balance Sheet | ||||
| Total Assets | ¥698,836M | ¥765,606M | ¥839,169M | ¥813,831M |
| Total Equity | ¥272,016M | ¥295,208M | ¥359,443M | ¥359,983M |
| Total Liabilities | ¥426,820M | ¥470,398M | ¥479,726M | ¥453,848M |
| Cash | ¥88,130M | ¥93,840M | ¥73,183M | ¥65,142M |
| Interest-bearing Debt | ¥280,502M | ¥317,832M | ¥299,790M | ¥280,919M |
| Equity Ratio | 38.92% | 38.56% | 42.83% | 44.23% |
| D/E Ratio | 1.03 | 1.08 | 0.83 | 0.78 |
| Cash Flow | ||||
| Operating CF | ¥42,993M | ¥26,847M | ¥76,729M | ¥93,406M |
| Investing CF | -¥46,528M | -¥44,093M | -¥55,374M | -¥47,869M |
| Financing CF | -¥5,452M | ¥19,956M | -¥52,373M | -¥48,855M |
| Free CF | -¥4,478M | -¥25,076M | ¥7,521M | ¥21,064M |
| Efficiency | ||||
| ROE | 11.49% | 13.78% | 15.53% | 13.75% |
| ROA | 4.47% | 5.31% | 6.65% | 6.08% |
Latest IR Information
-
Progress and Key Initiatives of the Mid-term Strategy Accelerate 2030|May 2026
Daxcel reviews the progress and key initiatives of Accelerate 2030, specifically highlighting growth investments and business strengthening measures, while introducing efforts toward achieving future targets.
Read more -
【Daicel】Dividend Forecast Revision|May 2026
Daicel revised its annual dividend forecast for the fiscal year ending March 2027 to 70 yen, an increase of 10 yen compared to the previous period. The DOE target was raised to over 5%, and the shareholder return ratio was...
Read more -
Detailed Explanation of the 2026 Mid-Term Management Plan and Business Strategy|May 2026
Daicel is advancing its business restructuring, new business initiatives, and corporate reforms based on the 2026 mid-term management plan, aiming for revenue and profit growth and maximizing capital efficiency.
Read more -
Financial Summary for the Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)
Net sales of 579.629 billion yen (down 1.2% YoY), operating income of 42.069 billion yen (down 31.0% YoY), net income attributable to owners of parent of 10.180 billion yen (down 79.4% YoY), reflecting decreased revenue and profit.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥1,458
Rating Score: 3.13 (Based on 8 analysts)
※1=Strong Buy, 5=Strong Sell
Daicel Corp stock (JP3424600001): earnings outlook and specialty chemicals focus - AD HOC NEWS ↗
Company Information
About
Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photoresists, optical lenses, and caprolactone derivatives; functional films and materials used in smartphones, PCs, TVs, and in-vehicle displays, polymers and solvents; and lenses used in VR, smartphones and various sensors. In addition, the company offers airbags inflators, pyro-fuses, and gas generators for seat belt pretensioners; acetic acid, acetic acid derivatives, acetate tow, ketene / diketene derivatives, cellulose acetate for LCD optical films, amines, and 1,3-butylene glycol; and reverse osmosis membrane and ultrafiltration membrane products, as well as water treatment systems. Further, it provides Engineering plastics comprising polyacetal, polybutylene terephthalate, polyphenylene sulfide, liquid crystal polymer, and cyclic olefin copolymer; AS resin, acetate plastics, water-soluble polymers, and barrier films for packaging; ABS resins, various polymer alloys, plastic compounds; Polyamide-12 and PEEK resin; and various molded containers. The company's products are used in transportation, electronics, medical care, personal care, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and is headquartered in Osaka, Japan.